JW (Cayman) Therapeutics Co. Ltd. (DE:JNY)
FRANKFURT:JNY
JNY Stock Chart & Stats
€0.26
€0.00(0.00%)
At close: 4:00 PM EST
€0.26
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.16 - €0.64
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€70.94M
Enterprise Value€330.20M
Total Cash (Recent Filing)€503.28M
Total Debt (Recent Filing)€262.67M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€34.57M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ImprovementA 55% top-line rebound alongside a ~43% gross margin suggests the business is scaling product adoption and improving unit economics. Durable revenue and margin gains reduce the dependency on financing to cover cost of goods sold and support reinvestment in R&D and commercialization over months.
Manageable LeverageDebt levels (D/E ~0.47) are moderate, meaning the company is not heavily levered relative to peers. This provides structural balance-sheet flexibility to fund clinical development or scale manufacturing without immediate refinancing pressure, assuming operating losses trend down.
Material Reduction In Cash BurnOperating cash outflows improved markedly in 2025, signaling stronger cash discipline or working-capital improvements. A sustained lower burn rate lengthens runway, lowers near-term financing needs, and makes a transition to self-sustaining cash generation more attainable over the coming quarters.
Bears Say
Persistent Deep LossesVery large negative margins and continued negative EBIT/EBITDA indicate the core business is not yet profitable. Persistent operating losses erode capital, require ongoing funding, and mean the company must materially improve margins or scale revenues substantially to reach durable profitability.
Equity Erosion Over TimeContinued losses have materially reduced shareholders' equity, weakening the capital base. This structural erosion increases dilution risk if management must issue equity, limits strategic optionality, and raises the bar for restoring reserves before the company can pursue larger investments.
Negative Free Cash Flow And Funding RelianceRepeated negative operating and free cash flow create a structural reliance on external financing. Over time this can lead to dilution or higher borrowing costs, constrain R&D and commercialization plans, and increase execution risk if capital markets tighten or investor appetite wanes.
JW (Cayman) Therapeutics Co. Ltd. News
JNY FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was €0.16 and its highest was €0.64 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is €70.94M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 72 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -€0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.086.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -€0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in DE:JNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.55%
12-Months-Change
Fundamentals
Return on Equity
-75.15%
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---